SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing heavy volume and a surge in bullish sentiment following an earnings report that highlighted improved profit margins and a strong pipeline for its AI infrastructure, leading many in the community to anticipate a significant price re-rating. While retail investors are aggressively debating the potential for a short squeeze and long-term valuation recovery, others remain cautious due to ongoing regulatory scrutiny and historical volatility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is capturing market attention as the community rallies behind its pivot from smartphones to a software-driven cybersecurity and physical AI company, bolstered by a significant Wall Street Journal spotlight and a high-profile presence at upcoming robotics expos. Investors are actively discussing the stock's potential for a major revaluation, citing robust institutional volume, a massive backlog in automotive and robotics technology, and the potential for a sustained breakout above its recent trading range.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors gear up for the imminent close of its Northern Data acquisition, a move widely viewed as a catalyst that could unlock significant AI and cloud computing potential. The community is heavily focused on the stock's record-high short interest and strong backing from Tether, leading to intense debates over the potential for a major short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant community buzz as investors anticipate potential global partnership announcements and updates regarding its AI-driven immunotherapy manufacturing technology. The discussion is heavily centered on a potential short squeeze, with retail traders pointing to high short interest and limited float as key drivers for a potential sharp upward move.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is trending as investors debate whether the company's recent earnings beat and strategic partnership with Disney signal a long-term turnaround or further decline. Community discussion is heavily divided, with some betting on a potential short squeeze fueled by high short interest and institutional interest, while others express frustration over past stock performance and skepticism regarding management's profitability targets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as market sentiment turns bullish, driven by expectations of a blockbuster year for Briumvi, strong commercial execution, and anticipation of upcoming trial readouts for subcutaneous formulations and Azer-cel. The community is actively discussing the potential for a strategic buyout and observing significant institutional accumulation, which many believe is positioning the stock for a breakout beyond current resistance levels.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors digest a positive earnings report showing significant revenue beats and reduced operating costs while keeping a close eye on the expanding Matrix-M platform, which is currently being explored for over 30 infectious disease and oncology applications. The community is actively debating the potential for future partnerships with global pharma giants and closely tracking activist investor pressure to optimize capital allocation and management structure.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently trending after an official determination from NOAA declared its deep-seabed mining application fully compliant, a key regulatory milestone that clarifies the path toward commercial recovery permits. The investment community is actively debating the significance of this development for long-term production timelines and the company's role in the critical minerals supply chain, while some investors monitor potential volatility associated with institutional selling and expiring options.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending after announcing a strategic manufacturing partnership with Cellipont Bioservices to advance its ERNA-101 ovarian cancer cell therapy toward clinical trials. Community sentiment is highly polarized, with retail traders focusing on the stock's low float and short-squeeze potential, while critics remain skeptical, highlighting the company's history of reverse splits and dilution.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant volatility and intense community debate as investors navigate a disconnect between its strong product demand and a persistent slide toward 52-week lows ahead of upcoming earnings. Market participants are actively discussing institutional manipulation, potential channel stuffing concerns, and the competitive impact of private-label energy drinks, while bulls continue to position for a post-earnings recovery fueled by the company's growth narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage.</li><li>However, the FDA issued a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application.</li><li>Analysts from Craig-Hallum and TD Cowen slashed price targets on the stock on Friday following the FDA decision.</li></ul>Shares of Grace Therapeutics (GRCE) are on track for their worst week since Sept. 2020, after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury, sparking price target cuts.Shares of the company are down 49% this week, if losses hold.<h2 class="st-heading-2">FDA Rejection</h2>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm.However, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/grce-stock-plunges-after-fda-rejects-brain-injury-drug-company-says-concerns-are-fixable/cZBQevVReTT">issued </a>a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.<h2 class="st-heading-2">Wall Street Weighs In</h2>Craig-Hallum lowered the firm's price target on Grace Therapeutics to $4 from $11 and kept a ‘Buy’ rating on the shares following the announcement. The firm believes Grace has enough runway to address the deficiencies highlighted by the FDA and an application resubmission, though shares are unlikely to move higher until further visibility is provided, it said.TD Cowen analyst Stacy Ku also lowered the firm's price target on Grace Therapeutics to $8 from $12 and kept a ‘Buy’ rating on the shares. The firm noted that GTx-104's rejection is related to CMC, with no requests for additional clinical data. Management will seek a meeting with the FDA, which should clarify resubmission timelines, the analyst said. The firm assumes a roughly 12-month delay, with potential for faster resolution.<h2 class="st-heading-2">Grace Chimes In</h2>“We are confident in the robust data package supporting our NDA (application) submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said on Thursday following the receipt of the FDA letter.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GRCE stock stayed within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user highlighted that the issues cited by the FDA are fixable and the stock will bounce back up.<stembedurl>https://www.stocktwits.com/h8ster/message/651317731</stembedurl>Another user dismissed the rejection and instead highlighted possible risks of dilution from capital raising initiatives.<stembedurl>https://www.stocktwits.com/Stockseeking/message/651266436</stembedurl><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> is down 8% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-on-track-for-best-week-ever-on-fda-push-for-psychedelics/cZBhaQDReck">CMPS On Track For Best Week Ever On FDA Push For Psychedelics</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


<ul class="summary-bullets"><li>FDA cited issues in the chemistry, manufacturing, and controls (CMC) and non-clinical sections of the company’s application.</li><li>The agency, however, did not request additional clinical data, the company highlighted.</li><li>The company expects to have a meeting with the FDA to determine the next steps ahead.</li></ul> Shares of Grace Therapeutics Inc. (GRCE) closed 45% lower on Thursday after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury.Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm. aSAH accounts for about 5% of all strokes and affects about 42,500 patients in the U.S., according to Grace. &nbsp;<h2 class="st-heading-2">Why The Rejection?</h2>The company said that the FDA issued it a complete response letter, in which the agency cites issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.The agency, however, did not request additional clinical data, the company highlighted. Grace submitted its application with positive results from the Phase 3 STRIVE-ON safety trial, which compared GTx-104, an injectable form of nimodipine, with its oral version. The study met its primary endpoint, showing a 19% reduction in clinically significant hypotension among patients treated with GTx-104.<h2 class="st-heading-2">Executive Optimism</h2>“We are confident in the robust data package supporting our NDA submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said. The company expects to have a meeting with the FDA to determine the next steps ahead.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GRCE stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism for the company fixing the issues.<stembedurl>https://www.stocktwits.com/Tradebub/message/651205728</stembedurl>Another user expressed optimism for the stock to rally while the company resubmits its application.<stembedurl>https://www.stocktwits.com/46e123/message/651201565</stembedurl><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> has added 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-spacex-merger-is-coming-biographer-tells-investors-you-are-investing-in-elon-musk/cZBQ47MReTR">Tesla-SpaceX Merger Is Coming: Biographer Tells Investors, ‘You’re Investing In Elon Musk, Not Procter &amp; Gamble’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 

<ul class="summary-bullets"><li>Grace Therapeutics’ NDA for GTx-104 was accepted by FDA last August</li><li>GTx-104 already received Orphan Drug Designation, which could grant seven years of market exclusivity in the U.S. if approved.</li><li>Patients on GTx-104 also recorded fewer ICU readmissions and shorter hospital stays, the company said.</li></ul>Shares of Grace Therapeutics (GRCE) are gaining investor attention ahead of a key decision from the U.S. Food and Drug Administration on its treatment for the highly fatal aneurysmal subarachnoid hemorrhage, with a verdict expected on April 23.<a href="https://stocktwits.com/symbol/INBX">GRCE shares</a> traded 1.7% higher in pre-market trading on Wednesday.<h2 class="st-heading-2">Data Shows Fewer ICU Admissions</h2>Last August, Grace Therapeutics announced that the FDA accepted its New Drug Application (NDA) for GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage (aSAH), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2026A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.The submission was backed by positive results from the Phase 3 STRIVE-ON safety trial, which compared GTx-104, an injectable form of nimodipine, with its oral version. The study met its primary endpoint, showing a 19% reduction in clinically significant hypotension among patients treated with GTx-104.Patients on GTx-104 also recorded fewer ICU readmissions and shorter hospital stays. Safety outcomes were comparable between the two groups, with no new concerns identified.GTx-104 has also received Orphan Drug Designation, which could grant seven years of market exclusivity in the U.S. if approved. The designation could also result in the waiver of FDA application user fees.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.One bullish user highlighted a potential rally given the “super low float.”<stembedurl>https://stocktwits.com/CharlieeMungerTWITS/message/650871175</stembedurl>Another user weighed in on trading in the stock if the approval was granted.<stembedurl>https://stocktwits.com/kintaro712/message/650971705</stembedurl>Year-to-date, the stock has gained around 37%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) will be releasing its Q3 2026 earnings before the market opens on Thursday, February 12. (View Earnings Report at...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Up 34.6% in January

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Sees Significant Increase in Short Interest

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 31,816 shares...

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

GRCE
Grace Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest GRCE News

GRCEGrace Therapeutics Inc.